Evidence map›Paper›PMID 19625659›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2009

Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells.

Harun Elmasri, Cagatay Karaaslan, Yaroslav Teper, Elisa Ghelfi, Meiqian Weng, Tan A Ince, Harry Kozakewich, Joyce Bischoff, Sule Cataltepe

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

182 citing papers in PubMed, 1 synthesis or guideline pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. A who's who of cell types in skeletal muscle.Communications biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Protective Role ofAdvanced biomedical research · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

122 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Harun ElmasriDivision of Newborn Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.
Cagatay Karaaslan
Yaroslav Teper
Elisa Ghelfi
Meiqian Weng
Tan A Ince
Harry Kozakewich
Joyce Bischoff
Sule Cataltepe
Brigham and Women's Hospital · USHarvard University · USBoston Children's Hospital · US

Funding

Training Program in Newborn and Developmental DiseasesT32HD007466 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI KOUREMBANAS, STELLA · 1994 to 2016
$8.0M
NICHD NIH HHS 5T32 HD007466-12NICHD NIH HHS T32 HD007466
6 · The paper itself

Abstract

Fatty acid binding protein 4 (FABP4) plays an important role in maintaining glucose and lipid homeostasis. FABP4 has been primarily regarded as an adipocyte- and macrophage-specific protein, but recent studies suggest that it may be more widely expressed. We found strong FABP4 expression in the endothelial cells (ECs) of capillaries and small veins in several mouse and human tissues, including the heart and kidney. FABP4 was also detected in the ECs of mature human placental vessels and infantile hemangiomas, the most common tumor of infancy and ECs. In most of these cases, FABP4 was detected in both the nucleus and cytoplasm. FABP4 mRNA and protein levels were significantly induced in cultured ECs by VEGF-A and bFGF treatment. The effect of VEGF-A on FABP4 expression was inhibited by chemical inhibition or short-hairpin (sh) RNA-mediated knockdown of VEGF-receptor-2 (R2), whereas the VEGFR1 agonists, placental growth factors 1 and 2, had no effect on FABP4 expression. Knockdown of FABP4 in ECs significantly reduced proliferation both under baseline conditions and in response to VEGF and bFGF. Thus, FABP4 emerged as a novel target of the VEGF/VEGFR2 pathway and a positive regulator of cell proliferation in ECs.

Indexed as

AnimalsCell ProliferationEndothelial CellsEndothelium, VascularFatty Acid-Binding ProteinsFibroblast Growth Factor 2HemangiomaHumansInfant, NewbornMaleMiceMice, Inbred C57BLMyocardiumPlatelet Endothelial Cell Adhesion Molecule-1Vascular Endothelial Growth FactorsFABP4 protein, humanFabp4 protein, mouseFatty Acid-Binding ProteinsFibroblast Growth Factor 2Platelet Endothelial Cell Adhesion Molecule-1Vascular Endothelial Growth Factors

Identifiers

PMID19625659
PMCPMC2775007
OpenAlexW2155126563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.